Q2 Earnings Estimate for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of NeuroPace in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of ($0.22) per share for the quarter, up from their prior estimate of ($0.23). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.46 EPS.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $22.52 million for the quarter, compared to analysts’ expectations of $21.85 million.

Several other equities research analysts have also recently weighed in on NPCE. JPMorgan Chase & Co. upped their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $17.00 target price on shares of NeuroPace in a research report on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on shares of NeuroPace in a report on Wednesday, May 28th. They issued a “buy” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, NeuroPace presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

NeuroPace Price Performance

Shares of NPCE opened at $12.94 on Monday. The company has a 50 day moving average price of $12.90 and a 200-day moving average price of $12.37. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.98. The stock has a market capitalization of $424.42 million, a PE ratio of -12.94 and a beta of 2.03. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Financial Advocates Investment Management increased its holdings in shares of NeuroPace by 27.8% during the 4th quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after purchasing an additional 5,000 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in NeuroPace in the fourth quarter valued at $129,000. Bank of New York Mellon Corp increased its holdings in NeuroPace by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company’s stock valued at $328,000 after buying an additional 5,133 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of NeuroPace by 440.4% in the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after purchasing an additional 52,829 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of NeuroPace by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock valued at $3,615,000 after purchasing an additional 5,781 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the firm’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares of the company’s stock, valued at $51,325,454.15. This trade represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.20% of the stock is currently owned by corporate insiders.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.